Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rocket Pharmaceuticals is a late-stage biotechnology company developing first-in-class gene therapies for rare genetic diseases. Its lead programs include AAV and LVV-based therapies targeting cardiovascular and hematologic disorders. The company has multiple programs in pivotal or late-stage trials, including RP-A501 for Danon disease, which recently experienced an FDA clinical hold following a patient death in Phase 2. Other programs remain on track, with regulatory milestones achieved in the US and Europe[5][8][9].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rocket Ventures.